# A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer

> **NCT06760364** · PHASE1 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 21 (estimated)

## Conditions studied

- Advanced Pancreatic Cancers

## Interventions

- **DRUG:** CHT102

## Key facts

- **NCT ID:** NCT06760364
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-25
- **Primary completion:** 2027-12-24
- **Final completion:** 2039-12-24
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06760364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06760364, "A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06760364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*